Last reviewed · How we verify

NCT05357859

Vitamin D for Cognition in Bipolar Disorder

Completed NA Last updated 22 November 2023
What this trial tests

NA trial testing solubilized vitamin D3 in Bipolar Disorder in 21 participants. Completed in 20 November 2023.

Timeline
3 May 2022
Primary endpoint
17 November 2023
20 November 2023

Quick facts

Lead sponsorTaipei City Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment21
Start date3 May 2022
Primary completion17 November 2023
Estimated completion20 November 2023
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Taipei City Hospital

Who can join

Adults 20 to 65, any sex, with Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Conduct randomized double-blind controlled trial (RCT), to examine the effects of vitamin D on cognitive performance in euthymic BD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Bipolar Disorder

Currently open trials in the same condition.

Other Taipei City Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05357859.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing